Drugs / OV101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03109756 | Apr → Nov 2017 | Angelman syndrome, fragile X syndrome | Healx AI | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03697161 | Sep 2018 → Feb 2020 | fragile X syndrome | Healx AI | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03882918 | Jan 2019 → Jun 2021 | Angelman syndrome | Healx AI | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OV101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03882918 ↗ |
| Known as | gaboxadol | “Gaboxadol (OV101) is a δ-subunit-selective, extrasynaptic GABAA receptor agonist” PMID 34690787 ↗ Oct 2021 |